The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced awards to establish four Cooperative Research Centers (CRCs) focused on developing vaccines to prevent sexually transmitted infections (STIs). The grants, totaling $41.6 million over five years, will support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea and chlamydia. At the end of the program, each center is expected to identify at least one candidate vaccine ready for testing in clinical trials.
- Published
- 10 May 2019
- From
-
National Institute of Allergy and Infectious Diseases
Prescription of generic versions of antiretroviral drugs for
treatment and pre-exposure prophylaxis (PrEP) as soon as they come off patent would
save the NHS £7 billion between
- Published
- 10 May 2019
- By
- Keith Alcorn
A plan to cut US funding to South Africa for HIV programmes is likely to be reversed – as long as the quality of services for people living with HIV is increased, say health NGOs. “The turnaround is a major victory for people living with HIV in the country, as critical resources will be restored,” eight NGOs are quoted in The Times as saying.
- Published
- 02 May 2019
- From
-
Medical Brief
Arguably the biggest challenge facing South Africa’s HIV response today is how to support many more people living with HIV to start and, importantly, stay on treatment. Doing this in the context of a dysfunctional healthcare system will not be easy, but cannot be shied away from. Yet instead of receiving commitment to do what it will take to make this happen, South Africa is facing the threat of dramatic cuts in U.S. government funding that risk derailing future progress, gambling with people’s health and lives.
- Published
- 25 April 2019
- From
-
Health GAP
The proposed rule would allow plans to exclude certain drugs in those protected classes, including antiretrovirals.
- Published
- 25 April 2019
- From
-
Poz
Profit seems to be the only logic driving medicine prices, with some African countries paying more for medicine than European countries, and US citizens paying some of the highest medicine prices in the world. While there are global efforts to rein in pharmaceutical companies’ excessive profiteering from sickness, trying to remove the secrecy around prices is complicated.
- Published
- 15 April 2019
- From
-
Daily Maverick
A stalemate over who would take more patients on to PrEP trial has ended. London councils have agreed to increase places on city PrEP trial.
- Published
- 15 April 2019
- From
-
Gay Star News
When HIV drugmaker ViiV announced in late 2017 that it had received Food and Drug Administration (FDA) approval for Juluca (dolutegravir/rilpivirine), the first effective two-drug, single-pill HIV regimen in the modern treatment era, community activists hoped that its price would reflect the fact that it contained one drug fewer than three-drug tablets like Complera (rilpivirine/tenofovir disoproxil fumarate/FTC), Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide), Stribild (cobicistat/elvitegravir/FTC/tenofovir disoproxil fumarate), and Triumeq (abacavir/dolutegravir/lamivudine), all of which are generally priced between $2,600 and $3,500 a month in the U.S.
- Published
- 15 April 2019
- From
-
The Body
In a surprise move barely six weeks after announcing that SA was to get an extra $1.2bn to support its HIV/AIDS programmes over the next two years, US global AIDS coordinator Deborah Birx said Pepfar’s programmes are performing so poorly in SA that funding should be cut from the start of the next US financial year, which begins on October 1.
- Published
- 12 April 2019
- From
-
Business Day
John Biggs, Mayor of Tower Hamlets has written to Matt Hancock the Secretary of State for health, to call for the funding of HIV treatment that could stop the spread of HIV, saving the NHS millions of pounds.
- Published
- 11 April 2019
- From
-
Tower Hamlets council
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...